Arterial hypertension as a risk factor for cognitive impairments development

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Arterial hypertension (AH) is one of the most significant risk factors for cognitive impairments development. Presence of high blood pressure in middle age of individual could be considered as a precondition for a decline in cognitive abilities in the future. AH leads to damage of the vascular wall, development of endothelial dysfunction, microcirculation disorders, decreased cerebral perfusion, and progression of neurodegenerative damage. One of the pathogenetic mechanisms of cognitive disorders formation is oxidative stress, which justifies the use of drugs with antioxidant action, including in case of arterial hypertension. Mexidol has direct antioxidant activity due to its ability to inactivate free radicals and increase activity of antioxidant enzymes. The results of MEMO study subanalysis indicate the advisability of using sequential therapy (parenteral administration followed by oral administration) with Mexidol + Mexidol FORTE 250 in clinical practice for patients with AH.

全文:

受限制的访问

作者简介

Anna Bogolepova

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (Pirogov University); Federal Center for Brain and Neurotechnologies of FMBA of Russia

编辑信件的主要联系方式.
Email: annabogolepova@yandex.ru
ORCID iD: 0000-0002-6327-3546
SPIN 代码: 6775-0279

MD, Dr. Sci. (Medicine), professor, professor of the Department of neurology, neurosurgery and medical genetics of the Institute of neuroscience and neurotechnologies, head of the Center for Cognitive and Psychoemotional Health

俄罗斯联邦, Moscow; Moscow

参考

  1. Levine DA, Springer MV, Brodtmann A. Blood pressure and vascular cognitive impairment. Stroke. 2022;53(4):1104–13. PMID: 35264009. PMCID: PMC9141568. https://doi.org/10.1161/strokeaha.121.036140
  2. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. Circulation. 2016;134(6):441–50. PMID: 27502908. PMCID: PMC4979614. https://doi.org/10.1161/circulationaha.115.018912
  3. Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C et al. Prevalence, awareness, treatment, and control of hypertension in China: Data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. 2017;390(10112):2549–58. PMID: 29102084. https://doi.org/10.1016/S0140-6736(17)32478-9
  4. Баланова Ю.А., Шальнова С.А., Имаева А.Э., Капустина А.В., Муромцева Г.А., Евстифеева С.Е. с соавт. Распространенность артериальной гипертонии, охват лечением и его эффективность в Российской Федерации (данные наблюдательного исследования ЭССЕ-РФ-2). Рациональная фармакотерапия в кардиологии. 2019;15(4):450–466. [Balanova YuA, Shalnova SA, Imaeva AE, Kapustina AV. Muromtseva GA, Evstifeeva SE et al. Prevalence, awareness, treatment and control of hypertension in Russian Federation (data of observational ESSE-RF-2 study). Ratsional’naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2019;15(4):450–466 (In Russ.)]. EDN: ZRWESV. https://doi.org/10.20996/1819-6446-2019-15-4-450-466
  5. Кобалава Ж.Д., Котовская Ю.В., Виллевальде С.В., Баранова Е.И., Богачев Р.С., Волкова Н.И. с соавт. Результаты Российской научно-практической программы АРГУС-2: возможности улучшения контроля артериальной гипертонии путем рационального использования диуретиков. Лечебное дело. 2007;(3):60–67. [Kobalava ZhD, Kotovskaya YuV, Villevalde SV, Baranova EI, Bogachev RS, Volkova NI et al. Results of the Russian scientific and practical program ARGUS-2: Possibilities of improving control of arterial hypertension by rational use of diuretics. Lechebnoe delo = General Medicine. 2007;(3):60–67 (In Russ.)]. EDN: MSYQOZ.
  6. Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И. с соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):230–329. [Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI et al. Clinical practice guidelines for hypertension in adults. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2024;29(9):230–329 (In Russ.)]. EDN: GUEWLU. https://doi.org/10.15829/1560-4071-2024-6117
  7. Ou YN, Tan CC, Shen XN, Xu W, Hou XH, Dong Q et al. Blood pressure and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 209 prospective studies. Hypertension. 2020;76(1):217–25. PMID: 32450739. https://doi.org/10.1161/hypertensionaha.120.14993
  8. Livingston G, Huntley J, Liu KY, Costafreda SG, Selbæk G, Alladi S et al. Dementia prevention, intervention, and care: 2024 report of the Lancet Standing Commission. Lancet. 2024;404(10452):572–628. PMID: 39096926. https://doi.org/10.1016/S0140-6736(24)01296-0
  9. Levine DA, Galecki AT, Langa KM, Unverzagt FW, Kabeto MU, Giordani B et al. Blood pressure and cognitive decline over 8 years in middle-aged and older Black and White Americans. Hypertension. 2019;73(2):310–18. PMID: 30624986. PMCID: PMC6450556. https://doi.org/10.1161/hypertensionaha.118.12062
  10. Gottesman RF, Albert MS, Alonso A, Coker LH, Coresh J, Davis SM et al. Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol. 2017;74(10):1246–54. PMID: 28783817. PMCID: PMC5710244. https://doi.org/10.1001/jamaneurol.2017.1658
  11. Derby CA, Hutchins F, Greendale GA, Matthews KA, Sternfeld B, Everson-Rose SA et al. Cardiovascular risk and midlife cognitive decline in the study of women’s health across the nation. Alzheimers Dement. 2021;17(8):1342–52. PMID: 33710770. PMCID: PMC9210934. https://doi.org/10.1002/alz.12300
  12. Lande MB, Kupferman JC. Blood pressure and cognitive function in children and adolescents. Hypertension. 2019;73(3):532–40. PMID: 30686086. PMCID: PMC6374155. https://doi.org/10.1161/hypertensionaha.118.11686
  13. Mahinrad S, Kurian S, Garner CR, Sedaghat S, Nemeth AJ, Moscufo N et al. Cumulative blood pressure exposure during young adulthood and mobility and cognitive function in midlife. Circulation. 2020;141(9):712–24. PMID: 31747780. PMCID: PMC7135652. https://doi.org/10.1161/circulationaha.119.042502
  14. Nordstrom P, Nordstrom A, Eriksson M, Wahlund LO, Gustafson Y. Risk factors in late adolescence for young-onset dementia in men: A nationwide cohort study. JAMA Intern Med. 2013;173(17):1612–18. PMID: 23939347. https://doi.org/10.1001/jamainternmed.2013.9079
  15. Haverkamp RA, Melis RJF, Claassen JAHR, de Heus RAA. Day-to-day home blood pressure variability and all-cause mortality in a memory clinic population. J Alzheimers Dis. 2021;85(3):1219–31. PMID: 34924378. https://doi.org/10.3233/jad-215002
  16. Zhu Y, Li C, Gao D, Huang X, Zhang Y, Ji M et al. Associations of blood pressure trajectories with subsequent cognitive decline, dementia and mortality. J Prev Alzheimers Dis. 2024;11(5):1426–34. PMID: 39350390. https://doi.org/10.14283/jpad.2024.91
  17. Li C, Zhu Y, Ma Y, Hua R, Zhong B, Xie W. Association of cumulative blood pressure with cognitive decline, dementia, and mortality. J Am Coll Cardiol. 2022;79(14):1321–35. PMID: 35393012. https://doi.org/10.1016/j.jacc.2022.01.045
  18. Waldstein SR, Giggey PP, Thayer JF, Zonderman AB. Nonlinear relations of blood pressure to cognitive function: The Baltimore Longitudinal Study of Aging. Hypertension. 2005;45(3):374–79. PMID: 15699446. https://doi.org/10.1161/01.HYP.0000156744.44218.74
  19. Korf ESC, White LR, Scheltens P, Launer LJ. Midlife blood pressure and the risk for hippocampal atrophy: The Honolulu-Asia aging study. Hypertension. 2004;44(1):29–34. PMID: 15159381. https://doi.org/10.1161/01.HYP.0000132475.32317.bb.
  20. Walker KA, Sharrett AR, Wu A, Schneider ALC, Albert M, Lutsey PL et al. Association of midlife to late-life blood pressure patterns with incident dementia. JAMA. 2019;322(6):535–45. PMID: 31408138. PMCID: PMC6692677. https://doi.org/10.1001/jama.2019.10575
  21. Kim Y, Lim JS, Oh MS, Yu KH, Lee JS, Park JH et al. Blood pressure variability is related to faster cognitive decline in ischemic stroke patients: PICASSO subanalysis. Sci Rep. 2021;11(1):5049. PMID: 33658545. PMCID: PMC7930263. https://doi.org/10.1038/s41598-021-83945-z
  22. de Heus RAA, Tzourio C, Lee EJL, Opozda M, Vincent AD, Anstey KJ et al. Association between blood pressure variability with dementia and cognitive impairment: A systematic review and meta-analysis. Hypertension. 2021;78(5):1478–89. PMID: 34538105. PMCID: PMC8516811. https://doi.org/10.1161/hypertensionaha.121.17797
  23. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–46. PMID: 32738937. PMCID: PMC7392084. https://doi.org/10.1016/S0140-6736(20)30367-6
  24. Peters R, Peters J, Booth A, Anstey KJ. Trajectory of blood pressure, body mass index, cholesterol and incident dementia: Systematic review. Br J Psychiatry. 2020;216(1):16–28. PMID: 31368428. https://doi.org/10.1192/bjp.2019.156
  25. Lennon MJ, Lam BCP, Lipnicki DM, Crawford JD, Peters R, Schutte AE et al. Use of antihypertensives, blood pressure, and estimated risk of dementia in late life: An individual participant data meta-analysis. JAMA Netw Open. 2023;6(9):e2333353. PMID: 37698858. PMCID: PMC10498335. https://doi.org/10.1001/jamanetworkopen.2023.33353
  26. . Mahinrad S, Bennett DA, Sorond FA, Gorelick PB. Blood pressure variability, dementia, and role of antihypertensive medications in older adults. Alzheimers Dement. 2023;19(7):2966–74. PMID: 36656086. PMCID: PMC10354219. https://doi.org/10.1002/alz.12935
  27. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ. Midlife blood pressure and dementia: The Honolulu-Asia aging study. Neurobiol Aging. 2000;21(1):49–55. PMID: 10794848. https://doi.org/10.1016/s0197-4580(00)00096-8
  28. Peters R, Xu Y, Fitzgerald O, Aung HL, Beckett N, Bulpitt C et al. Blood pressure lowering and prevention of dementia: An individual patient data meta-analysis. Eur Heart J. 2022;43(48):4980–90. PMID: 36282295. https://doi.org/10.1093/eurheartj/ehac584
  29. Hughes D, Judge C, Murphy R, Loughlin E, Costello M, Whiteley W et al. Association of blood pressure lowering with incident dementia or cognitive impairment: A systematic review and meta-analysis. JAMA. 2020;323(19):1934–44. PMID: 32427305. PMCID: PMC7237983. https://doi.org/10.1001/jama.2020.4249
  30. Cunningham EL, Todd SA, Passmore P, Bullock R, McGuinness B. Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2021;5(5):CD004034. PMID: 34028812. PMCID: PMC8142793. https://doi.org/10.1002/14651858.CD004034.pub4
  31. Ding J, Davis-Plourde KL, Sedaghat S, Tully PJ, Wang W, Phillips C et al. Antihypertensive medications and risk for incident dementia and Alzheimer’s disease: A meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol. 2020;19(1):61–70. PMID: 31706889. PMCID: PMC7391421. https://doi.org/10.1016/S1474-4422(19)30393-X
  32. den Brok MGHE, van Dalen JW, Abdulrahman H, Larson EB, van Middelaar T, van Gool WA et al. Antihypertensive medication classes and the risk of dementia: A systematic review and network meta-analysis. J Am Med Dir Assoc 2021;22(7):1386–95.e15. PMID: 33460618. https://doi.org/10.1016/j.jamda.2020.12.019
  33. Santisteban MM, Iadecola C, Carnevale D. Hypertension, neurovascular dysfunction, and cognitive impairment. Hypertension. 2023;80(1):22–34. PMID: 36129176. PMCID: PMC9742151. https://doi.org/10.1161/hypertensionaha.122.18085
  34. Ashby JW, Mack JJ. Endothelial control of cerebral blood flow. Am J Pathol. 2021;191(11):1906–16. PMID: 33713686. https://doi.org/10.1016/j.ajpath.2021.02.023
  35. Pacholko A, Iadecola C. Hypertension, neurodegeneration, and cognitive decline. Hypertension. 2024;81(5):991–1007. PMID: 38426329. PMCID: PMC11023809. https://doi.org/10.1161/hypertensionaha.123.21356
  36. Щулькин А.В. Современные представления об антигипоксическом и антиоксидантном эффектах Мексидола. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;(118:12-2):87–93. [Shchulkin AV. A modern concept of antihypoxic and antioxidant effects of Mexidol. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12-2):87–93 (In Russ.)]. EDN: PPTGEP. https://doi.org/10.17116/jnevro201811812287
  37. Щулькин А.В. Влияние Мексидола на развитие феномена эксайтотоксичности нейронов in vitro. Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;112(2):35–39. [Shchulkin AV. The effect of Mexidol on the development of the phenomenon of excitotoxicity of neurons in vitro. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(2):35–39 (In Russ.)]. EDN: PBZBVV.
  38. Щулькин А.В., Якушева Е.Н., Черных И.В. Распределение Мексидола в структурах головного мозга, его клеточных элементах и субклеточных фракциях. Журнал неврологии и психиатрии им. С.С. Корсакова. 2014;114(8):70–73. [Shchulkin AV, Yakusheva EN, Chernykh IV. The distribution of Mexidol in the rat’s brain and its subcellular fractions. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(8):70–73 (In Russ.)]. EDN: STXUSB.
  39. Воронина Т.А., Литвинова С.А., Гладышева Н.А. Известные и новые представления о механизме действия и спектре эффектов Мексидола. Журнал неврологии и психиатрии им. С.С. Корсакова. 2025;125(5):22–33. [Voronina TA, Litvinova SA, Gladysheva NA. The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(5):22–33 (In Russ.)]. EDN: ECPVEY. https://doi.org/10.17116/jnevro202512505122
  40. Воронина Т.А., Иванова Е.А. Комбинированное применение Мексидола с известными лекарственными средствами. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(4):115–124. [Voronina TA, Ivanova EA. Combined administration of mexidol with known medicines. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):115–124 (In Russ.)]. EDN: ZSOSEH. https://doi.org/10.17116/jnevro2019119041115
  41. Чуканова Е.И., Чуканова А.С. Эффективность и безопасность препарата Мексидол ФОРТЕ 250 в рамках последовательной терапии у пациентов с хронической ишемией мозга. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(9):39–45. [Chukanova EI, Chukanova AS. Efficacy and safety of the drug Mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9):39–45 (In Russ.)]. EDN: PEGQWJ. https://doi.org/10.17116/jnevro201911909139
  42. Федин А.И., Захаров В.В., Танашян М.М., Чуканова Е.И., Маджидова Е.Н., Щепанкевич Л.А., Остроумова О.Д. Результаты международного многоцентрового рандомизированного двойного слепого плацебо-контролируемого исследования оценки эффективности и безопасности последовательной терапии пациентов с хронической ишемией мозга препаратами Мексидол и Мексидол ФОРТЕ 250 (исследование МЕМО). Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(11):7–16. [Fedin AI, Zakharov VV, Tanashyan MM, Chukanova EI, Madzhidova EN, Shchepankevich LA, Ostroumova OD. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11):7–16 (In Russ.)]. EDN: OBNTNH. https://doi.org/10.17116/jnevro20211211117
  43. Захаров В.В., Остроумова О.Д., Кочетков А.И., Клепикова М.В., Федин А.И. Международное многоцентровое рандомизированное двойное слепое плацебо-контролируемое исследование оценки эффективности и безопасности последовательной терапии пациентов с хронической ишемией мозга препаратами Мексидол и Мексидол ФОРТЕ 250 (исследование МЕМО): результаты субанализа у пациентов с артериальной гипертонией. Терапия. 2023;9(1):145–159. [Zakharov VV, Ostroumova OD, Kochetkov AI, Klepikova MV, Fedin AI. International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol® and Mexidol® FORTE 250 in patients with chronic brain ischemia (MEMO): Subanalysis in patients with arterial hypertension. Terapiya = Therapy. 2023;9(1):145–159 (in Russ.)]. EDN: SPQRTS. https://doi.org/10.18565/therapy.2023.1.145-159
  44. Мартынов А.И., Танашян М.М., Малявин А.Г., Боголепова А.Н., Боровкова Н.Ю., Елисеева Л.Н. с соавт. Резолюция совета экспертов «Возможности нейропротективной терапии у пациентов с артериальной гипертензией и когнитивными нарушениями». Терапия. 2023;9(10):148–158. [Martynov AI, Tanashyan MM, Malyavin AG, Bogolepova AN, Borovkova NYu, Eliseeva LN et al. Resolution of the Expert Council “Possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders”. Terapiya = Therapy. 2023;9(10):148–158 (in Russ.)]. EDN: TZWYWX. https://doi.org/10.18565/therapy.2023.10.148-158

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2025